These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29278866)

  • 1. Is patient exposure preapproval and postapproval a determinant of the timing and frequency of occurrence of safety issues?
    Pacurariu AC; Hoeve CE; Arlett P; Genov G; Slattery J; Sturkenboom MCJM; Straus SMJM
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):168-173. PubMed ID: 29278866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
    Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
    Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-approval safety issues with innovative drugs: a European cohort study.
    Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
    Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between concerns toward adverse reactions during pre-approval drug reviews and the post-approval addition of clinically significant adverse reactions to package inserts: A retrospective analysis of pre-approval drug review reports and safety updates.
    Watanabe K; Murakami M; Masuyama K; Ishiguro C; Matsuda T
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1265-1276. PubMed ID: 30252199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
    Ikeda J; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1393-1401. PubMed ID: 30094880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
    Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.
    Naci H; Smalley KR; Kesselheim AS
    JAMA; 2017 Aug; 318(7):626-636. PubMed ID: 28810023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
    Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
    Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
    Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014.
    Pinnow E; Amr S; Bentzen SM; Brajovic S; Hungerford L; St George DM; Dal Pan G
    Clin Pharmacol Ther; 2018 Aug; 104(2):390-400. PubMed ID: 29266187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
    Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-approval appending of CSARs to drug package inserts: an analysis of the types of adverse reactions and time to addition.
    Tamura N; Ishiguro C; Matsuda T
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):166-75. PubMed ID: 24737526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Br J Clin Pharmacol; 2015 Oct; 80(4):716-26. PubMed ID: 25808713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses.
    Gentili M; Pozzi M; Peeters G; Radice S; Carnovale C
    Curr Clin Pharmacol; 2018; 13(1):28-39. PubMed ID: 29412117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
    Botelho SF; Martins MA; Vieira LB; Reis AM
    J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan.
    Nakayama H; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2019 Feb; 33(1):45-52. PubMed ID: 31933266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
    Hauben M; Reich L; Chung S
    Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.